Saxagliptin - Wikipedia, the free encyclopedia
Saxagliptin , previously identified as BMS-477118, is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. [1]
Dipeptidyl peptidase-4 inhibitor - Wikipedia, the free encyclopedia
Drugs belonging to this class are vildagliptin [5] (marketed in the EU by Novartis under the trade name Galvus), sitagliptin [6], saxagliptin (being developed by Bristol-Myers Squibb, ...
ONGLYZATM (saxagliptin) With Metformin as Initial ...
ONGLYZA TM (saxagliptin) With Metformin as Initial Combination Therapy Significantly Lowered A1C and Demonstrated Significant Improvements Across Key Measures of Glucose Control in ...
Alogliptin and Saxagliptin May Fight Diabetes on RxList
Learn more about the two new drugs Alogliptin and Saxagliptin used to treat type 2 diabetes. ... 2 New Drugs May Help Fight Diabetes. Drugs, Called Alogliptin and Saxagliptin, Are ...
BMS, AstraZeneca present saxagliptin data - FierceBiotech
Bristol-Myers Squibb and AstraZeneca presented results from a 24-week Phase III study of Onglyza (the proposed trade name for saxagliptin). When used in combination with metformin ...
Significant New Data For Investigational Diabetes Drug Saxagliptin ...
New data presented for the first time at the 44th European Association for the Study of Diabetes (EASD) Annual Meeting have added to the growing body of evidence, which ...
New Data for Investigational Diabetes Drug Saxagliptin Demonstrates ...
AstraZeneca corporate information, one of the world's leading pharmaceutical companies providing effective prescription drugs and innovative prescription medicines in many ...
ONGLYZA(TM) (saxagliptin) Demonstrated Significant Reductions in Key ...
Capital Gains. These gains don't cause pain. A capital gain is the amount of money you pocket by selling one of your investments for more than you paid for it.
New Data for Investigational Diabetes Drug Saxagliptin Demonstrates ...
New Data for Investigational Diabetes Drug Saxagliptin Demonstrates Potential for Type 2 Diabetes Treatment. - ROME, September 9 /PRNewswire/ -- Results from a 24-week Phase III ...
Diabetes News from dLife.com: ONGLYZA™ (saxagliptin) With Metformin ...
September 9, 2008 (Press Release) - Results from a 24-week Phase III study presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ...
